Academia
There is no one-size-fits-all algorithm for AI that enables drug developers to quickly identify the features they seek. Instead, researchers are selecting best-of-breed algorithms for customized analytics.
Researchers have discovered a potential treatment target for Down syndrome, Th17 cells could mitigate microbiome-linked diseases and electroacupuncture in Parkinson’s disease.
There are several approaches on the horizon in ALS, a space that is gaining momentum. BioSpace spoke with GeNeuro, NeuroSense and the Tisch MS Research Center about their progress.
A new report estimates that if cannabis was to be legalized across the United States, it could cut into pharmaceutical sales by billions of dollars.
A cell and gene therapy accelerator formed by Mayo Clinic, Hibiscus BioVentures and Innoforce is officially up and running, the partners announced this week.
A trial evaluating generic drugs against severe COVID-19 provided data showing their overall ineffectiveness, and COVID-19-related lawsuits continue to pile up.
Researchers at Case Western University looked at the real-world experiences of 13,644 patients who were treated with Paxlovid or Lagevrio (molnupiravir) during the first half of 2022.
Researchers recently developed a peptide called A1R-CT that could ultimately have therapeutic applications in both epilepsy and Alzheimer’s disease.
The 3D-printed acoustic hologram could be very important to the delivery of certain therapeutics for Alzheimer’s Disease (AD) and other neurological disorders.
BMS, 2seventy bio, HUTCHMED and AstraZeneca celebrate cancer trial wins, while mutated zebrafish eyes reveal potentially important insights into cell death.
PRESS RELEASES